Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics Reports Second Quarter 2018 Financial Results
July 26, 2018 4:02 PM EDT-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $122.4 Million in the Second Quarter-
-ADCETRIS ECHELON-2 Top-line Results Expected in Early Fourth Quarter 2018-
-Enrollment Completed in Pivotal Trial Cohort of Enfortumab Vedotin in Metastatic Urothelial Cancer; EV Top-line Results Expected in First Half of 2019-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2018. The company... More
